The use of adjuvant chemotherapy for stage III colorectal cancer is well established, but the use of this approach in patients with stage II colon cancer is more controversial. Midgley and Kerr highlight data from the QUASAR 1 trial, which provide compelling evidence for the use of adjuvant chemotherapy. The use of combination therapeutic options, the rationale for considering morphologic or molecular features to select and individualize therapy, and the crucial question of which patients would benefit most from adjuvant chemotherapy, are discussed.
- Rachel Midgley
- David J Kerr